Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 25;6(4):otae063.
doi: 10.1093/crocol/otae063. eCollection 2024 Oct.

What to Expect When Switching to a Biosimilar: A US Healthcare Professional's Perspective

Juanita Belton  1 , Nicholas D'Apice  2
Affiliations

What to Expect When Switching to a Biosimilar: A US Healthcare Professional's Perspective

Juanita Belton et al. Crohns Colitis 360. .

Abstract

As biosimilars become more available, many patients with inflammatory bowel disease may experience having their treatment switched from a reference product to a biosimilar. In this communication, a physician assistant and a pharmacist discuss the patient experience when switching to a biosimilar.

Keywords: biologic; biosimilar; drug switching.

PubMed Disclaimer

Conflict of interest statement

J.B. and N.D. declare no relevant or material financial interests that relate to the research described in this paper.

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Plain language explanation of biosimilars. A, Biologic reference products vs. biosimilars. B, FDA approval process of biologic reference products and biosimilars.
Figure 2.
Figure 2.
A, Patient journey initiating biologic treatment. B, Ideal patient journey switching to a biosimilar.
See this image and copyright information in PMC

References

    1. U.S. FDA. What Are “Biologics” Questions and Answers. Vol. 2023: U.S. Food & Drug Administration; 2018.
    1. U.S. FDA. Biosimilar and Interchangeable Biologics: More Treatment Choices. Vol. 2023: U.S. Food & Drug Administration; 2023.
    1. U.S. FDA. Statement From Sarah Yim, M.D., Acting Director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s Continued Progress Facilitating Competition in The Biologic Marketplace With Approval of 25th Biosimilar Product. Vol. 2023: U.S. Food & Drug Administration; 2019.
    1. Al-Naqqash M, Castañeda-Hernández G, Chiang SC, et al. Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer? Future Oncol. 2024;20(9):481-491. doi: https://doi.org/10.2217/fon-2023-0756 - DOI - PubMed
    1. Mulcahy A, Buttorff C, Finegold K, et al. Projected US savings from biosimilars, 2021-2025. Am J Manag Care. 2022;28(7):329-335. doi: https://doi.org/10.37765/ajmc.2022.88809 - DOI - PubMed

LinkOut - more resources